Propranolol prevents the development of heart failure by restoring FKBP12.6-mediated stabilization of ryanodine receptor

Circulation. 2002 Mar 19;105(11):1374-9. doi: 10.1161/hc1102.105270.

Abstract

Background: In heart failure, protein kinase A-mediated hyperphosphorylation of ryanodine receptors (RyRs) in sarcoplasmic reticulum (SR) causes dissociation of FKBP12.6 from RyRs. This results in an abnormal Ca2+ leak through RyRs, possibly leading to cardiac dysfunction. In the present study, we assess whether beta-blockers can correct this defect in RyR in tachycardia-induced heart failure and thereby improve cardiac function.

Methods and results: SRs were isolated from dog left ventricular muscles (normal group, 4 weeks of rapid right ventricular pacing with or without propranolol [P(+) or P(-)]). End-diastolic and end-systolic diameters both increased less in P(+) than P(-), associated with a smaller decrease in fractional shortening in P(+). In SR from P(-), a prominent Ca2+ leak was observed, and FK506 (which dissociates FKBP12.6 from RyR) did not induce an additional Ca2+ leak. However, there was no appreciable Ca2+ leak in SR from P(+), although FK506 induced a Ca2+ leak as in normal SRs. In SR from P(+), an FK506-induced conformational change in RyR, which was virtually absent in SR from P(-), was observed as in normal SRs. Both the stoichiometry of FKBP12.6 versus RyR, assessed by [3H]FK506 and [3H]ryanodine binding assays, and the protein expression of FKBP12.6, assessed by Western blot analysis, were restored by propranolol toward the levels seen in normal SRs.

Conclusions: Low-dose propranolol corrects the defective interaction of FKBP12.6 with RyR (restoration of RyR conformational change and prevention of Ca2+ leak from RyR), apparently resulting in an attenuation of intracellular Ca2+ overload and hence preventing the development of left ventricular remodeling in heart failure.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / pharmacology
  • Animals
  • Calcium / metabolism
  • Cardiac Pacing, Artificial
  • Diastole / drug effects
  • Disease Models, Animal
  • Dogs
  • Heart Failure / physiopathology*
  • Heart Failure / prevention & control*
  • Heart Ventricles / drug effects
  • Heart Ventricles / metabolism
  • Hemodynamics / drug effects
  • In Vitro Techniques
  • Myocardium / metabolism*
  • Phosphorylation / drug effects
  • Propranolol / pharmacology*
  • Protein Binding / drug effects
  • Protein Conformation / drug effects
  • Ryanodine Receptor Calcium Release Channel / metabolism*
  • Sarcoplasmic Reticulum / drug effects
  • Sarcoplasmic Reticulum / metabolism
  • Systole / drug effects
  • Tacrolimus / pharmacology
  • Tacrolimus Binding Proteins / metabolism*
  • Ventricular Remodeling / drug effects

Substances

  • Adrenergic beta-Antagonists
  • Ryanodine Receptor Calcium Release Channel
  • Propranolol
  • Tacrolimus Binding Proteins
  • tacrolimus binding protein 1B
  • Calcium
  • Tacrolimus